Abstract: The present invention relates to empty porous particles having a diameter between 0.1 and 1000 ?m, as measured by e.g. SEM, for use in diagnosis, prevention and/or postponement of neurodegenerative diseases, or for prevention and/or postponement of degeneration of neurons and glia. The invention also relates to a method of identifying biomarkers for use in diagnosis.

Abstract: The present invention relates to a process for manufacturing porous silica particles comprising at least one bioactive compound, whereby the particles are adapted for lung, nasal, sublingual and/or pharyngeal delivery of said at least one bioactive compound and have an MMAD between 0.5 and 15 ?m with a GSD less than 2.5. The invention also relates to a pharmaceutical composition comprising said silica particles and a use of the silica particles in the diagnoses, prevention and/or treatment of local and/or systemic disorders, such as disorders of the lung, nose, sublingual and/or pharynx.

Abstract: The present invention relates to a compressed pharmaceutical dosage form comprising one or more active pharmaceutical ingredients at a concentration between 2 and 15% w/w, porous particles, having a diameter between 1 and 100 ?m, at a concentration between 10 and 50% w/w and optionally one or more excipients. The active pharmaceutical ingredient is in admixture with and/or loaded into said particles, whereby a ratio of unloaded versus loaded ingredient is between 100:1 and 1:100. The porosity of the dosage form is more than 5% and less than 45% and the hardness of the dosage form is more than 5 N and less than 30 N using a Schleuniger hardness type tester.

Abstract: The present invention relates to a process for manufacturing porous silica particles comprising at least one bioactive compound, whereby the particles are adapted for lung, nasal, sublingual and/or pharyngeal delivery of said at least one bioactive compound and have an MMAD between 0.5 and 15 ?m with a GSD less than 2.5. The invention also relates to a pharmaceutical composition comprising said silica particles and a use of the silica particles in the diagnoses, prevention and/or treatment of local and/or systemic disorders, such as disorders of the lung, nose, sublingual and/or pharynx.

Abstract: A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Abstract: A pharmaceutical or cosmetic composition, comprising a substantially poorly water-soluble pharmaceutical active ingredient; and a nanoporous folic acid material, wherein the active pharmaceutical ingredient is incorporated inside the nanoporous channels of the particles.

Abstract: A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Abstract: The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.

Abstract: A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Abstract: A pharmaceutical or cosmetic composition, comprising a substantially poorly water-soluble pharmaceutical active ingredient; and a nanoporous folic acid material, wherein the active pharmaceutical ingredient is incorporated inside the nanoporous channels of the particles.

Abstract: A method for the preparation of enhanced fluorescent folic acid mesoporous material, multifluorescent mesoporous materials, their novel properties and applications such as: a mesoporous fluorescent composition suitable for printing identification marks on metals, glass, plastic, ceramics, or paper which are visible only when excited by an external radiation; and applications in life science applications such as diagnostic, biodistribution markers, and targeted drug delivery applications.

Abstract: The invention concerns a method for manufacturing nanoporous metal oxide or metal active sites frameworks in which the metal oxide precursor is distributed into the framework in the form of a metal soap surfactant. The invention also covers a nanostructure framework comprising metal oxide active sites which are evenly distributed in the framework.

Abstract: A method for the preparation of an inorganic porous oxide material, comprising the following steps: a) dissolving an alumina precursor in a mixture of a non-aqueous solvent and an acid; b) dissolving a pore agent in a non-aqueous solvent; c) mixing together the solutions obtained in step a) and b); d) adding a morphology controller to the reaction mixture of step c); e) evaporating the reaction mixture of step d); and f) removing the morphology controller and the pore agent from the product of step e).

Abstract: The invention concerns a method for manufacturing nanoporous metal oxide or metal active sites frameworks in which the metal oxide precursor is distributed into the framework in the form of a metal soap surfactant. The invention also covers a nanostructure framework comprising metal oxide active sites which are evenly distributed in the framework.